DUBLIN--(BUSINESS WIRE)--The "Antibiotics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
The global market for antibiotics should grow from $44.4 billion in 2020 to reach $65.4 billion by 2025 at a compound annual growth rate (CAGR) of 8.1% during the period of 2020-2025.
The antibiotics market growth outlook is positive with significant growth potential for cell wall inhibitor and protein inhibitor antibiotic drugs. There is pressure on antibiotic drug manufacturers to offer antimicrobial-resistant drugs at affordable prices. At the same time, factors such as rising disposable incomes and increasing spending on healthcare in emerging markets, increasing grants from government agencies for antibiotic drugs research and development, and rising incidence of infectious diseases are contributing to the growth of the market.
Pharmaceutical companies and governments are increasingly working together in partnerships and collaborations to provide funding and implement incentive programs for the research and development (R&D) of antibiotics. These partnerships provide financial and technical assistance across different clinical development phases to the pharmaceutical companies.
Various programs, such as the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), the Innovative Medicines Initiative's (IMI's) New Drugs for Bad Bugs (ND4BB) program, Biomedical Advanced Research and Development Authority's (BARDA) Broad Spectrum Antimicrobials Program, and Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), have been implemented for the development of novel antibiotics by focusing on R&D gaps.
Additionally, The Davos Declaration was signed in January 2016 by more than 100 companies and trade associations which included Allergan, AstraZeneca, GSK, Pfizer and Sanofi. This declaration focused on investments in R&D to meet public health needs, reducing the development of antimicrobial resistance and improving access to antibiotics.
Pharmaceutical companies are increasingly adopting 3D printing technology for the discovery and development of new antibiotics to reduce manufacturing costs and increase production efficiency. For instance, in 2018, a 3D-printed fluorescence imaging box (PFIbox) was developed by McMaster University's laboratory for antibiotics discovery. This box is capable of analyzing more than 6,000 samples of bacteria at a time and provides vital information on bacterial response.
The report includes:
- 28 data tables and 16 additional tables
- Comprehensive overview of the global market for antibiotics within the pharmaceutical industry
- Analyses of the global market trends, with data corresponding to market size for 2018-2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
- Latest information on market growth drivers and opportunities, industry supply chain structure, regulatory developments, technological advancements, and demographic shifts shaping the overall antibiotics marketplace
- Evaluation of market growth during the forecast period, and deep dive of market share analysis data basis of product type, product, route of administration, end-user and geographical region
- Country specific data and analysis for the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa
- Impact of COVID-19 on the pharmaceutical market for antibiotics and an outlook of short-term vs. long-term impacts of COVID-19 pandemic
- Identification of the companies best positioned to meet the global market demand for antibiotic drugs on the basis of their proprietary technologies, M&A deals, collaborations, JVs and other strategic alliances
- Detailed company profiles of the major global corporations, including Abbott, F. Hoffmann-La Roche AG, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Pfizer and Sanofi
Key Topics Covered:
Chapter 1: Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
Chapter 2: Summary and Highlights
Chapter 3: Market and Technology Background
- Overview of Antibiotics
- Common Side Effects of Antibiotics
- Classification of Antibiotics
- Cell Wall Inhibitors
- Protein Inhibitors
- DNA Inhibitors
- Other Antibiotic Classes
- Overview of Gram-negative and Gram-positive Bacteria
- Route of Administration
- Trends in the Market for Antibiotics
- Funding for New Antibiotic Development
- Increasing Focus on Antibiotic Drug Development by Smaller Pharmaceutical Firms
- Growing Public-Private Partnerships
Chapter 4: Market Dynamics
- Market Drivers
- Growth of the Global Pharmaceutical Market Driven by Antibiotics
- Rise in Geriatric Population and Infection Rate
- Increasing Prevalence of Hospital-acquired Infections
- Improved Awareness about Diseases and their Antibiotics
- Market Restraints
- Antibiotic-resistant Infections
- Genericization of Antibiotics and Drugs
- Declining Research and Development (R&D) Investment
- Side Effects of Antibiotics
- Market Opportunities
- Market Expansion into Emerging Countries
- Development of Novel Antibacterial Agents
Chapter 5: Market Breakdown by Product
- Global Market for Antibiotics by Product
- Cell Wall Inhibitors
- Protein Inhibitors
- DNA Inhibitors
- Other Types of Inhibitors
Chapter 6: Market Breakdown by Route of Administration
- Global Market for Antibiotics by Route of Administration
- Oral Antibiotics
- Topical Antibiotics
- Other Routes of Administration
Chapter 7: Market Breakdown by Region
Chapter 8: Impact of COVID-19 on the Pharmaceutical Industry
- Short-term Impact
- Change in Demand
- Shift of Communication and Promotions to Remote Interactions
- Research and Development Changes
- Long-term Impact
- Delayed Approvals for Non-COVID-related Pharmaceutical Products
- Self-sufficiency in Pharma Industry
- Pharmaceutical Industry Growth Slow-Down
- Changes in Consumption Trends in Health-related Products
Chapter 9: Clinical Developments and Pipeline Products
- Respiratory Tract Infections
Chapter 10: Value Chain Analysis
- China is a Becoming a Center of Microbial Threats
Chapter 11: Regulatory Scenario
- FDA and International Regulation
- Recent Regulatory Reforms
- Ketek Case Study
Chapter 12: Competitive Landscape
- Global Company Market Share Analysis
- Mergers, Collaborations, Partnerships and Acquisitions
Chapter 13: Company Profiles
- Abbott
- F. Hoffmann-La Roche AG
- Glaxosmithkline Plc
- Johnson & Johnson
- Merck & Co., Inc.
- Mylan N.V.
- Pfizer Inc.
- Sanofi
For more information about this report visit https://www.researchandmarkets.com/r/5y11gd
